Skip to main content
. 2021 May 6;2021(5):CD012972. doi: 10.1002/14651858.CD012972.pub2

7. Summary of studies: time to initiate treatment.

Study Country Design Setting Smear
Median days (IQR)
Xpert 
Median days (IQR)
Comparison
Mupfumi 2014 Zimbabwe RCT specialized hospital 8 (3 to 23) 5 (3 to 13)  P = 0.26
Theron 2014a multiple RCT primary healthcare facilities 15% (115/178)  23% (168/744) P = 0.0002
Churchyard 2015 South Africa cluster‐RCT primary healthcare facility 10 7  
Cox 2014 South Africa cluster‐RCT primary healthcare facility 8 (2 to 27) 4 (2 to 8) HR 0.76 (0.63 to 0.92) P = 0.005
Agizew 2019a Botwsana stepped‐ wedge public HIV clinics 22 (3 to 51) 6 (2 to 17) P = 0.005
Durovni 2014 Brazil stepped‐wedge clinics using laboratories 11.4 (8.5 to 14.5)  8.1 (5.4 to 9.3) P = 0.04
Van den Handel 2015 South Africa before/after district, sub‐district, and primary healthcare facilities 11.5 (6 to 24) 1 (0 to 2)  
Yoon 2012 Uganda before/after national referral hospital 1 (0 to 5) 0 (0 to 2) P = 0.06
Schmidt 2017 South Africa before/after primary healthcare facilities 5 (2 to 14) 4 (2 to 8)  P < 0.001
van Kampen 2015 Indonesia before/after drug‐resistant TB clinics 42 (25 to 55) 15 (7 to 51) P < 0.001

HR: hazard ratio
IQR: interquartile range
RCT: randomized controlled trial
TB: tuberculosis

Theron 2014a reported the proportion of participants initiating treatment on the day of diagnosis.

Di Tanna 2019 included an individual participant data (IPD) meta‐analysis for time to treatment for Churchyard 2015; Cox 2014; Mupfumi 2014; and Theron 2014a. The HR was estimated to be 1.00 (95% CI 0.75 to 1.32) for Xpert MTB/RIF compared to smear microscopy, adjusting for age and sex.